2026-01-18 - Analysis Report
**Johnson & Johnson's Financial Report (2026-01-17)**
====================================================

### Overview
---------------------------------------------
Johnson & Johnson is a multinational healthcare company providing medical devices, pharmaceuticals, and consumer packaged goods.

### Return Rate and Divergence
------------------------------
* Cumulative return of review stock: 60.63%
* Cumulative return of comparison stock (S&P 500, VOO): 93.36%
* Divergence: 32.20, relative divergence: 39.80% (indicating the current position is in the upper quartile of past data)

### Alpha, Beta Analysis
---------------------
**Year** | **CAGR** | **MDD** | **Alpha** | **Beta** | **Cap(B)**
---------|---------|--------|-----------|---------|-----------
2016-2018 | 6.0%   | 16.8%  | 3.0%      | 0.7     | 310.9B
2017-2019 | 18.0%  | 16.8%  | 1.0%      | 0.7     | 351.4B
2018-2020 | 19.0%  | 16.8%  | -2.0%     | 0.7     | 379.2B
2019-2021 | 32.0%  | 10.7%  | -12.0%    | 0.6     | 412.2B
2020-2022 | 8.0%   | 13.8%  | 10.0%     | 0.5     | 425.6B
2021-2023 | -18.0% | 13.8%  | -19.0%    | 0.3     | 377.6B
2022-2024 | -30.0% | 13.8%  | -50.0%    | 0.2     | 348.4B
2023-2025 | 30.0%  | 13.8%  | -32.0%    | 0.1     | 498.6B

### Recent Stock Price Fluctuations
--------------------------------

* Current close price: $218.66
* Last-market close: -$0.91 (4.1% decline)
* 5-day SMA: $216.03 (1.3% decline)
* 20-day SMA: $208.94 (4.2% decline)
* 60-day SMA: $201.95 (8.3% decline)

### RSI, PPO Index, and Delta_Previous_Relative_Divergence Analysis
----------------------------------------------------------------
* Market Risk Indicator (MRI): 0.80 (medium investment recommended)
* RSI: 70.76
* PPO: 0.54
* Hybrid Signal: Buy
* Recent (20 days) relative divergence change: 12.20 (+)
* 7-day Rank change: -49 (-)
* 7-day Dynamic Expected Return change: 37.60 (+)
* Expected Return (%): -37.30%
* Expected excess return compared to S&P 500 if invested long-term: -37.30%

### Recent News & Significant Events
------------------------------------

* [2026-01-13] Here’s What Lifted Johnson & Johnson (JNJ) in Q4
* [2026-01-17] Johnson & Johnson $JNJ Shares Sold by GWN Securities Inc.
* [2025-12-30] More Upside For JNJ Stock In 2026?
* [2026-01-16] Johnson & Johnson Stock Capital Return Hits $159 Bil
* [2026-01-17] Johnson & Johnson stock slips — what traders watch before JNJ earnings
* [2026-01-14] Fund Update: 434,743 JOHNSON & JOHNSON (JNJ) shares added to Canoe Financial LP portfolio

### Analyst Opinions
--------------------

* Analyst Consensus:
	+ Key: Buy
	+ Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
	+ Opinions: 24
	+ Target Price (avg/high/low): 212.00 / 240.00 / 155.00

### Recent Earnings Analysis
-----------------------------

| Date | EPS | Revenue |
|------|-----|---------|
| 2025-10-22 | 2.14 | 23.99 B$ |
| 2025-07-24 | 2.3  | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |

### Quarterly Revenue and Profitability Analysis
------------------------------------------------

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

### Quarterly Capital and Profitability Analysis
-----------------------------------------------

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

### Comprehensive Analysis Summary
----------------------------------

Johnson & Johnson's financial report shows a decline in stock price with a cumulative return of 60.63% and a divergence of 32.20%. The Alpha, Beta analysis indicates stable performance with a mean of 2.16 (~Buy) from analyst opinions. The recent earnings analysis shows growth in EPS with a revenue of $23.99B in Q4 2025. The quarterly revenue and profitability analysis indicates a consistent profit margin of around 68%. The quarterly capital and profitability analysis shows a growth in ROE of 14.08% in Q3 2025.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.